Tags : Boston Pharmaceuticals

Novartis Signs License and Equity Investment Agreement with Boston Pharmaceuticals

Shots: Novartis out-licensed worldwide rights for its three drug candidates, including LYS228 & IID572 targeting carbapenem-resistant enterobacteriaceae (CRE) and MAK181 targeting Pseudomonas infections. Boston to pay an upfront, milestone and royalty payments on sales to Novartis Additionally, Novartis to get an equity stakes in two new companies formed together with Boston for development and commercialization […]Read More